Navigation Links
Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
Date:9/13/2010

SAN DIEGO, Sept. 13, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will host a conference call and webcast on Friday, September 17, 2010, at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) following the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting. The committee is scheduled to meet on September 16, 2010, to review the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena discovered and has developed, is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese or patients who are overweight (Body Mass Index > 27) and have at least one weight-related co-morbid condition.

The conference call may be accessed by dialing 877.303.6132 for domestic callers and 678.809.1062 for international callers. Please specify to the operator that you would like to join the "Lorcaserin" conference call. The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management and has completed a pivotal Phase 3 clinical trial program. Arena has filed an NDA for lorcaserin with the FDA, and the FDA has
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
2. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
3. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
5. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
6. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
8. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
9. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... The Taskforce representing Canada,s living victims ... that the Minister and Health Canada have put into this ... needs of the thalidomide survivors, and more than 70% of ... with annual adjustments for inflation. Certain of the ... based on the severity of their disability, tax free, with ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:5/24/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... sees many patients for concerns about hair loss. Although ... it is clear that there are environmental factors such ... hormone that can contribute. Since they offer a comprehensive ... of the peri and post-menopausal woman, they can help ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) has scheduled its next monthly ... the multidistrict litigation. According to court documents filed ... Illinois, the Conference will be convened on June ... Replacement Therapy Product Liability Litigation - MDL No. ...
(Date:5/24/2015)... 2015 A report out just ... single best option for avoiding cardiovascular disease is exercise ... was the single most powerful predictor of death and ... diabetes and family history of premature death -- a ... and lung fitness. , The Importance of Cardiovascular Screening ...
(Date:5/23/2015)... May 23, 2015 On Wednesday, May ... “the company has been the target of a sophisticated ... of the company’s ongoing Information Technology (IT) security efforts ... , The most notable attack on health insurers ... Inc., the nation’s second largest health insurer, revealed that ...
(Date:5/23/2015)... 23, 2015 Add High-Quality prismatic refractions into ... Studios. , It's as simple as dragging and dropping footage ... tool for full effect. , Including over 80 stunning ... 5k sensors making this the ultimate bundle for adding prismatic ... in this package are movie files designed for Final Cut ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2
... ... your brand, advertising campaign, competitors or product innovations. , ... (PRWEB) April 6, 2010 -- Six Degrees has ... affordable way to gather insights needed to optimize marketing strategies, increase advertising effectiveness, gather ...
... is weak , TUESDAY, April 6 (HealthDay News) -- A ... in fruits and vegetables helps protect against cancer. , U.S. ... in 10 European countries and found only a weak association ... risk. , The study did find that heavy drinkers who ...
... ARBOR, Mich.---The proportion of older middle-aged Americans who report ... 2007, in contrast to the disability decline that has ... to a new study by the RAND Corporation and ... in the proportion of Americans aged 50 to 64 ...
... support care between office visits, boost efficiency and convenience, ... the April Health Affairs suggests how to ... patients how they like it and what they want. ... health information technology they use is meeting their needs ...
... ... Builders of the Dawn reveals a new world growing all around us and the keys to ... ... planet in 2010 may make some people want to go into hiding. But the authors of ...
... 5, 2010 The Clinical Practice Model Resource Center ... practice guidelines for healthcare, today launched its first Web-based ... online edition of its award-winning guidelines supports new and ... collaboration with a model that helps improve practice at ...
Cached Medicine News:Health News:Fruits, Veggies Have Modest Effect on Cancer Risk 2Health News:Middle-aged Americans report more mobility-related disabilities 2Health News:Middle-aged Americans report more mobility-related disabilities 3Health News:Want better health information technology? Ask patients how they want it 2Health News:The Practical Visionary Offers Eight Keys to Surviving and Thriving in the 21st Century, 2Health News:The Practical Visionary Offers Eight Keys to Surviving and Thriving in the 21st Century, 3Health News:The Practical Visionary Offers Eight Keys to Surviving and Thriving in the 21st Century, 4Health News:The Practical Visionary Offers Eight Keys to Surviving and Thriving in the 21st Century, 5Health News:The CPM Resource Center launches Web-based clinical practice guidelines 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: